腔内支架技术治疗自发性孤立性肠系膜上动脉夹层

目的探讨腔内支架技术治疗自发性孤立性肠系膜上动脉夹层（spontaneous isolated dissection of superior mesenteric artery,SIDSMA）的安全性及有效性。方法回顾性分析2009年1月～2011年4月16例接受血管腔内支架治疗的SIDSMA的临床资料。结果均手术顺利,12例行单层裸支架释放,4例行双层裸支架释放。术后腹痛症状改善15例,无变化1例。术后6个月CTA复查,16例均支架通畅,14例假腔消失,2例支架外造影剂显影。结论对于未合并夹层破裂出血、肠坏死的症状性SIDSMA,腔内支架治疗是一种安全、有效、微创的治疗选择。     

自发性孤立性肠系膜上动脉夹层的诊疗分析

目的分析自发性孤立性肠系膜上动脉夹层(SISMAD)的影像学表现、治疗方案及预后。方法回顾性分析25例SISMAD患者的资料,分析其影像学特征、分型、治疗方法及随访记录。结果 25例患者中,Ⅰ型3例,Ⅱa型14例,Ⅱb型7例,Ⅲ型1例。2例无腹痛症状的患者,CTA分型为Ⅰ型,给予观察治疗。23例有症状的患者,保守治疗4例,其中Ⅱa型1例,Ⅱb型3例;血管腔内治疗18例,其中Ⅱa型13例,Ⅱb型4例,Ⅲ型1例;另有1例Ⅰ型患者经保守治疗后腹痛不缓解,复查CTA示假腔持续扩大,后转血管腔内治疗。随访时间1~43个月,中位随访时间8个月,随访期间患者均未出现腹痛等症状,CTA提示病变无进展,支架无移位并保持通畅。结论 SISMAD临床症状缺乏特异性,CTA可明确诊断并进行影像学分型,结合患者的症状,可指导临床治疗方案的制定。     

自发性孤立性肠系膜上动脉夹层的诊断及腔内支架治疗

目的:探讨自发性孤立性肠系膜上动脉夹层(SIDSMA)的诊断及治疗策略。方法:回顾分析2008—2010年期间15例接受血管腔内支架治疗的SIDSMA患者的临床资料。结果:15例均未合并夹层破裂出血或肠坏死。其中,12例行单层支架释放,3例行重叠支架释放,共释放支架18个(球扩式2个,自膨式16个)。术后及随访过程中,症状改善14例(93.3%),症状无变化1例(6.7%),无死亡,无肠坏死、腹腔出血、心肌梗死、脑血管意外、肾功能衰竭、消化道出血、肺炎等严重并发症发生。平均住院4(2~7)d。平均随访时间11(6~23)个月。15例患者术后6个月均行CTA复查,支架通畅率为100%,支架远端新发夹层1例(6.7%)。结论:对于未合并夹层破裂出血、肠坏死的SIDSMA患者,腔内支架治疗是一种安全、有效、微创的治疗选择。     

经皮腔内介入治疗自发性孤立性肠系膜上动脉夹层16例

目的探讨经皮腔内介入治疗自发性孤立性肠系膜上动脉夹层(spontaneous isolated superior mesenteric artery dissection,SISMAD)的效果和安全性。方法 2009年3月~2016年3月16例SISMAD(Yun血管影像学分型,Ⅰ型2例,Ⅱa型5例,Ⅱb型9例)经多穿刺入路,导丝通过病变段,然后行球囊扩张及支架植入。结果 16例接受介入治疗,其中2例保守治疗无效后采用介入治疗,手术技术成功率100%。16例共植入21枚自膨式裸支架,其中植入单层支架11例,双支架重叠术5例,术中造影显示肠系膜上动脉(superior mesenteric artery,SMA)真腔血流通畅。16例随访3~36个月(平均18.8月),均无腹痛症状发生,肠系膜上动脉CTA显示夹层动脉瘤不显影,支架内血流通畅。结论经皮腔内介入治疗SISMAD是一种安全、有效的方法。     

自发性孤立性肠系膜上动脉夹层的血管腔内介入治疗体会

目的评价血管腔内介入治疗自发性孤立性肠系膜上动脉夹层(spontaneous isolated superior mesenteric artery dissection,SISMAD)的有效性和安全性。方法回顾性分析2009年3月至2016年5月期间笔者所在医院收治的17例SISMAD患者的临床资料。根据Sakamoto血管影像学分型,Ⅰ型3例,Ⅱ型5例,Ⅲ型9例;3例Ⅰ型患者接受内科保守治疗,保守治疗不理想者及其他患者接受介入治疗。结果保守治疗成功1例,共16例接受介入治疗,技术成功率为100%;11例患者置入支架1枚,5例患者置入支架2枚;术中造影检查显示肠系膜上动脉(superior mesenteric artery,SMA)真腔血流通畅,无严重并发症发生。17例患者均获随访,随访时间3~36个月,平均19个月,17例患者均无腹痛症状发生,SMA的CTA检查显示夹层动脉瘤不显影,SMA和支架内血流通畅。结论腔内介入治疗SISMAD是一种微创、安全及有效的方法。     

累及肠系膜上动脉的Stanford B型夹层主动脉瘤的治疗

目的探讨Stanford B型主动脉夹层动脉瘤(aortic dissection aneurysm,ADA)引起肠道缺血(intestinal ischemia)的治疗。方法回顾分析2005年1月至2006年2月8例累及肠系膜上动脉(superior mesenteric artery,SMA)的Stanford B型急慢性ADA的治疗方法。其中有5例SMA完全开口于假腔,为了预防腔内修复(endovascular repair,EVR)术后出现肠道缺血,先行髂动脉-SMA人工血管旁路术,再行腔内修复降主动脉夹层动脉瘤。1例ADA急性期出现肠坏死行小肠部分切除,SMA内膜切除及固定。1例EVR术后肠缺血缓解。1例EVR术后7个月出现SMA夹层,保守治疗。结果所有5例行内脏动脉重建者均获得成功,无围手术期死亡。所有8例降主动脉夹层动脉瘤EVR均获得成功,1例出现Ⅱ型内瘘,无肠道缺血症状出现。术后随访平均7.5(1～14)个月,CTA示SMA通过移植血管显影通畅;人工血管内支架无移位、断裂;出现Ⅱ型内瘘患者术后3个月随访CTA内瘘消失。结论内脏动脉受累的Stanford B型急慢性ADA,术前正确的判断及合理的手术方式往往可以挽救患者的生命,减少主动脉破裂的危险以及内脏缺血致死的可能。     

腔内修复术治疗Stanford B型胸主动脉夹层临床分析

目的 探讨腔内修复术治疗胸主动脉夹层的方法和疗效.方法 回顾性分析78例StanfordB型胸主动脉夹层的临床资料.术前均采用CT血管造影(CTA)或磁共振血管造影(MRA)对患者进行评估;在数字减影血管造影( DSA)的监控下经股动脉将带膜支架型人工血管置入胸主动脉内膜破口处,封闭夹层近端第一破口;术后即行DSA.于术后1,3,6个月及1年以后每隔1年行CTA随访,随访患者生存状况、内漏类型及残余夹层真假腔内径.结果 腔内修复后,术中造影发现Ⅰ型内漏6例,其中2例内漏在cuff植入后消失;2例近端内漏行球囊扩张后内漏消失;2例漏血少,假腔显影浅淡,未予处理;术后3个月发现1例内漏仍持续存在,但假腔直径未见增大.Ⅱ型内漏2例,因漏血少,未予处理.术后6个月发现其中自行封闭1例;另1例内漏仍存在,但假腔直径未见增大.78例患者中,术中封闭左锁骨下动脉者15例.其中2例出现左上肢窃血综合征,并伴有乏力症状;2例2年后出现脑梗死;1例6个月后出现Stanford A型夹层而行升主动脉置换术.其余患者无心、肺、肾功能衰竭及截瘫等严重并发症.结论 近期随访结果表明,腔内修复术治疗Stanford B型胸主动脉夹层安全、有效;内漏是该手术的主要并发症.     

腔内介入治疗自发性孤立性肠系膜上动脉夹层的短中期疗效

目的:探讨腔内介入治疗自发性孤立性肠系膜上动脉夹层(SISMAD)的短中期临床效果。方法:回顾性分析2009年3月—2016年8月收治的16例SISMAD患者资料,根据Sakamoto分型,其中I型3例(18.75%),II型3例(18.75%),III型10例(62.5%)。结果:1例I型患者经保守治疗效果满意,2例I型患者、3例II型患者、5例III型患者行单支架植入术,5例III型患者行双支架植入术(其中1例III型患者真腔狭窄约95%,行球囊扩张后植入2枚支架)。所用支架均为自膨式裸支架。随访1~34个月,中位时间16个月,均未再发相关性腹痛等症状,腹部CTA显示夹层假腔不显影,支架无移位、变形,支架腔内无狭窄、闭塞。结论:腔内介入治疗SISMAD的短中期效果好,但其长期效果需进一步观察。     

裸支架在孤立性内脏动脉夹层治疗中的应用

目的:探讨裸支架在内脏动脉夹层治疗中的安全性及疗效。方法:2008年4月—2012年3月,6例内脏动脉夹层患者接受裸支架腔内治疗。其中,肠系膜上动脉夹层5例,腹腔干动脉夹层1例,分别采用单层或双层裸支架叠加技术隔绝夹层破口及瘤体。结果:6例手术均顺利,无并发症发生,腹腔干动脉夹层患者与1例肠系膜上动脉夹层患者植入双层裸支架后假腔即刻不显影,另4例植入单层或双层裸支架3个月后CT或彩超复查提示假腔闭塞、真腔通畅。结论:采用单层裸支架或双层裸支架叠加技术,是治疗内脏动脉夹层可行、有效、安全的方法。     

主动脉夹层的腔内支架植入治疗体会

目的 探讨带膜支架腔内植入治疗Stanford B型主动脉夹层的效果.方法 对2002年1月至2007年9月间15例Stanford B型主动脉夹层的患者实行了血管造影和血管腔内带膜支架植入手术治疗.结果 除1例出现胸背部轻度疼痛外,其余患者症状完全消失,全部患者在随访期间均未出现术前症状.结论 带膜支架腔内植入治疗Stanford B型主动脉夹层是一种安全有效的方法.     

维生素D受体在糖尿病肾病足细胞损伤及蛋白尿缓解中的作用

目的探讨维生素D受体(VDR)在糖尿病肾病(DKD)足细胞中的表达水平及在足细胞损伤及蛋白尿缓解中的作用。方法(1)本研究纳入了65例诊断患有2型糖尿病(伴或不伴蛋白尿)的患者,并纳入了25例年龄和性别相匹配的健康体检者为对照组。根据白蛋白/肌酐(ACR)的尿排泄比例对2型糖尿病患者进行分组,分别为无蛋白尿(ACR<30 mg/g,n=24)、微量白蛋白尿(ACR 30~300 mg/g,n=18)和临床蛋白尿(ACR>300 mg/g,n=23)。另选择25例经肾活检确诊的DKD患者作为DKD组。正常肾脏组织标本均取自泌尿外科同一时期肾脏肿瘤切除患者10例。将各组检测指标进行对比,同时采用实时定量PCR、ELISA法和免疫组化法检测VDR在各组患者的血液、尿液样本和肾脏组织中的表达情况,以及使用Pearson相关分析分析VDR与尿蛋白的相关性。(2)在2型糖尿病肾病小鼠模型中对上述结果进行验证,将遗传背景均为C57BLKs/J的雄性db/db小鼠及同窝出生的db/m小鼠,随机分为正常对照组(A组)、DKD对照组(B组)、DKD二甲基亚砜处理组(C组)、DKD帕立骨化醇(VDR激动剂)处理组(D组),C、D组连续腹腔注射处理8周,对照组不做任何处理。小鼠10周龄时开始连续干预8周,在小鼠22周龄(开始干预后12周)检测各组小鼠体重、血、尿生化指标对比;Western印迹法检测β⁃catenin、VDR的变化;免疫荧光观察足细胞标志蛋白podocin及足细胞损伤蛋白α⁃SMA的表达变化。结果(1)与正常健康对照组相比,无蛋白尿组、微量白蛋白尿组和临床蛋白尿组的糖尿病患者血浆中VDR的mRNA和蛋白水平均较低(均P<0.05);与无蛋白尿组的糖尿病患者相比,微量白蛋白尿组和临床蛋白尿组的糖尿病患者血浆中VDR的mRNA和蛋白水平均较低(均P<0.05)。(2)与正常健康对照组相比,无蛋白尿糖尿病组和DKD组患者血浆中VDR的mRNA和蛋白水平均较低(均P<0.05);与无蛋白尿糖尿病组患者相比,DKD组患者血浆中VDR的mRNA和蛋白水平亦较低(均P<0.05)。(3)免疫组化结果显示,DKD组肾组织中VDR的表达明显少于正常对照组。(4)DKD患者血浆中VDR mRNA相对水平与ACR呈负相关(r=-0.342,P<0.05)。(5)各组尿液上清液中VDR的水平与血浆中的水平呈相反趋势。(6)Western印迹结果显示,B组、C组肾小球足细胞β⁃catenin蛋白表达高于D组(均P<0.05),VDR蛋白的表达低于D组(均P<0.05);免疫荧光结果显示,B组、C组肾小球足细胞podocin的表达低于D组(均P<0.05),α⁃SMA的表达高于D组(均P<0.05)。结论VDR高表达缓解DKD足细胞损伤及蛋白尿。     

Comparison of University of Wisconsin and University of Pittsburgh solutions for heart transplantation

The effectiveness of University of Wisconsin (UW) and University of Pittsburgh (UP) solutions for the preservation of rat hearts was compared. Lewis rat hearts were preserved with UW (group A, n=45) or UP (group B, n=45) solution for 0 or 24 h and then transplanted heterotopically into the recipients' abdomen. Ten recipients in each group were observed to obtain 1-week graft survival rates. Tissue water content and tissue content of adenine nucleotides were measured 2 h after transplantation in six grafts from each group. Six hearts preserved for 0 h and seven hearts preserved for 24 h were taken from each group 24 h after grafting for histopathology. The 1-week graft survival rates of groups A24 and B24 were 60% and 10%, respectively. In the 24-h preserved grafts, adenosine triphosphate (ATP) and energy charge [(ATP+adenosine diphosphate/2)/(ATP+adenosine diphosphate+adenosine monophosphate)] of groups A and B were 0.972±0.165 and 0.200±0.123 mg/g wet tissue (P<0.05) and 74.4% and 61.1% (P<0.05), respectively. The tissue water content of group A24 was 71.7%, whereas that of group B24 was 74.1% (P<0.05). Histopathology revealed more severe muscle edema and necrosis and infiltration of polymorphonuclear cells in group B24 than in group A24. We conclude that UW solution is more appropriate for rat heart preservation than UP solution.     

Role of Conventional and Diffusion-Weighted Magnetic Resonance Imaging of Spinal Treatment Protocol for Hydatid Disease

Objective:

To demonstrate the role of magnetic resonance imaging (MRI) in determining the treatment protocol for hydatid disease of the spine.

Design:

Case report; literature review.

Findings:

Diffusion-weighted MRI can help differentiate complicated infected hydatidosis from abscesses, epidermoid cysts from arachnoid cysts, and benign from malignant vertebral compression fractures. It is also helpful in differentiating between abscesses and necrotic tumors.

Conclusion:

Diffusion-weighted MRI can help differentiate between infections requiring immediate surgery and those that can be treated medically with antihelmintic treatment.     

罗伊适应模式对腹股沟疝无张力疝修补术后恢复情况的影响

目的探讨罗伊适应模式对患者腹股沟疝无张力疝修补术后恢复情况的影响。 方法将2016年1月至2019年5月在秦皇岛市第二医院择期进行无张力修补术治疗的120例腹股沟疝患者，按照随机数字法分为对照组和观察组，每组各60例。对照组采用常规护理治疗，观察组在对照组的基础上采用罗伊适应模式。比较2组患者的术后临床指标、心理状态、围手术期并发症发生情况及满意度。 结果术后观察组患者的首次排气时间、恢复正常饮食时间、离床活动时间和术后住院时间均低于对照组（P<0.05）；术后观察组患者的抑郁自评量表（SDS）和焦虑自评量表（SAS）评分显著低于对照组（P<0.05）；术后2组患者均无切口感染发生，2组患者尿潴留、急性疼痛、认知功能障碍、发热、血肿等发生率相比无统计学差异（P>0.05）；术后观察组患者护理满意度为96.67%，显著高于对照组的83.33%（P<0.05）。 结论在常规护理的基础上，罗伊适应模式用于患者腹股沟疝无张力修补围手术期，能有效改善术后患者的焦虑/抑郁情绪，不增加围手术期并发症，促进术后患者的恢复及提高治疗满意度。     

Long-term follow-up of callotasis lengthening of the capitate after resection of the lunate for the treatment of stage III lunate necrosis

The callotasis lengthening technique was used to gradually lengthen the capitate after resection of the lunate in stage IIIa necrosis in 23 patients. Results of ten patients with a follow-up of at least 5 years showed rapid and sufficient callus formation in every patient regardless of age. The callotasis lengthening modification of the Graner II operation provides all advantages and avoids the major inconvenience of the traditional Graner II operation. There was no increased rate of disturbed fracture healing. Results of the DTPA-gadolinium MRI study did not show any significant impairment of vascularization within the region of the capitate bone. With the “intrinsic bone formation,” contrary to every other intercarpal arthrodesis at the wrist, there is no need for an additional bone graft.     

Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers

BACKGROUND: Sugammadex rapidly reverses rocuronium- and vecuronium-induced neuromuscular block. To investigate the effect of combination of sugammadex and rocuronium or vecuronium on QT interval, it would be preferable to avoid the interference of anaesthesia. Therefore, this pilot study was performed to investigate the safety, tolerability, and plasma pharmacokinetics of single i.v. doses of sugammadex administered simultaneously with rocuronium or vecuronium to anaesthetized and non-anaesthetized healthy volunteers. METHODS: In this phase I study, 12 subjects were anaesthetized with propofol/remifentanil and received sugammadex 16, 20, or 32 mg kg(-1) combined with rocuronium 1.2 mg kg(-1) or vecuronium 0.1 mg kg(-1); four subjects were not anaesthetized and received sugammadex 32 mg kg(-1) with rocuronium 1.2 mg kg(-1) or vecuronium 0.1 mg kg(-1) (n=2 per treatment). Neuromuscular function was assessed by TOF-Watch SX monitoring in anaesthetized subjects and by clinical tests in non-anaesthetized volunteers. Sugammadex, rocuronium, and vecuronium plasma concentrations were measured at several time points. RESULTS: No serious adverse events (AEs) were reported. Fourteen subjects reported 23 AEs after study drug administration. Episodes of mild headache, tiredness, cold feeling (application site), dry mouth, oral discomfort, nausea, increased aspartate aminotransferase and gamma-glutamyltransferase levels, and moderate injection site irritation were considered as possibly related to the study drug. The ECG and vital signs showed no clinically relevant changes. Rocuronium/vecuronium plasma concentrations declined faster than those of sugammadex. CONCLUSIONS: Single-dose administration of sugammadex 16, 20, or 32 mg kg(-1) in combination with rocuronium 1.2 mg kg(-1) or vecuronium 0.1 mg kg(-1) was well tolerated with no clinical evidence of residual neuromuscular block, confirming that these combinations can safely be administered simultaneously to non-anaesthetized subjects. Rocuronium and vecuronium plasma concentrations decreased faster than those of sugammadex, reducing the theoretical risk of neuromuscular block developing over time.     

Magnetic resonance imaging for the evaluation of rejection of a kindney allograft in the rat

Orthotopic DA (RT1^a) into Lewis (RT1¹) rat kidney allografts and control Lewis-into-Lewis grafts were assessed by magnetic resonance imaging (MRI) and perfusion measurement after intravenous injection of a superparamagnetic contrast agent. MRI anatomical scores (range 1–6) and perfusion rates were compared with graft histology (rank of rejection score 1–6). Not only acute rejection, but also chronic events were monitored after acute rejection was prevented by daily cyclosporine (Sandimmune) treatment during the first 2 weeks after transplantation. In acute allograft rejection (n=11), MRI scores reached the maximum value of 6 and perfusion rates were severely reduced within 5 days after transplantation; histology showed severe acute rejection (histologic score 5–6). In the chronic phase (100–130 days after transplantation), allografts (n=5) manifested rejection (in histology cellular rejection and vessel changes), accompanied by MRI scores of around 2–3 and reduced perfusion rates. Both in the acute and chronic phases, the MRI anatomical score correlated significantly with the histological score (Spearman rank correlation coefficient r _s 0.89, n=30, P<0.01), and perfusion rates correlated significantly with the MRI score or histological score (r _s values between-0.60 and -0.87, n=23, P<0.01). It is concluded that MRI represents an interesting tool for assessing the anatomical and hemodynamical status of a kidney allograft in the acute and chronic phases after transplantation.     

Cost-effectiveness of three combinations of antiemetics in the prevention of postoperative nausea and vomiting

Background. This study compares the cost-effectiveness of threecombinations of antiemetics in the prevention of postoperativenausea and vomiting (PONV). Methods. We conducted a prospective, double-blind study. NinetyASA I–II females, 18–65 yr, undergoing general anaesthesiafor major gynaecological surgery, with standardized postoperativeanalgesia (intrathecal 0.2 mg plus i.v. PCA morphine), wererandomly assigned to receive: ondansetron 4 mg plus droperidol1.25 mg after induction and droperidol 1.25 mg 12 h later (Group1); dexamethasone 8 mg plus droperidol 1.25 mg after inductionand droperidol 1.25 mg 12 h later (Group 2); ondansetron 4 mgplus dexamethasone 8 mg after induction and placebo 12 h later(Group 3). A decision analysis tree was used to divide eachgroup into nine mutually exclusive subgroups, depending on theincidence of PONV, need for rescue therapy, side effects andtheir treatment. Direct cost and probabilities were calculatedfor each subgroup, then a cost-effectiveness analysis was conductedfrom the hospital point of view. Results. Groups 1 and 3 were more effective (80 and 70%) thanGroup 2 (40%, P=0.004) in preventing PONV but also more expensive.Compared with Group 2, the incremental cost per extra patientwithout PONV was €6.99 (95% CI, –1.26 to 36.57) forGroup 1 and €13.55 (95% CI, 0.89–132.90) for Group3. Conclusion. Ondansetron+droperidol is cheaper and at least aseffective as ondansetron+ dexamethasone, and it is more effectivethan dexamethasone+droperidol with a reasonable extra cost. Br J Anaesth 2003; 91: 589–92     

不同尿钙水平的Gitelman综合征患者临床特点比较

目的观察不同尿钙水平Gitelman综合征(GS)患者的临床特点,探讨尿钙在GS疾病临床分型中的价值。方法收集2016—2018年来自中国国家罕见病注册系统(NRSC)、在北京协和医院行SLC12A3基因检测诊断为GS患者的临床资料,分析其尿钙特点,比较不同尿钙水平患者的临床和实验室检查指标。氢氯噻嗪试验按照标准操作流程进行,测定患者基线和用药后3 h内氯离子排泄分数改变量的最大值(ΔFECl)。结果共有83例GS患者被纳入研究,其中低尿钙患者53例(63.86%)。低尿钙组尿钙/肌酐比明显低于非低尿钙组[(0.085±0.058)mmol/mmol比(0.471±0.284)mmol/mmol,t=7.349,P<0.001]。两组患者在年龄、性别、估算肾小球滤过率、血压、血尿电解质水平、代谢性碱中毒方面差异均无统计学意义。低尿钙组患者乏力(χ2=4.595,P=0.032)及多尿(χ2=5.778,P=0.016)发生比例低于非低尿钙组,两组患者在其他临床症状方面差异无统计学意义。低尿钙和非低尿钙组各有16例患者行氢氯噻嗪试验,中位ΔFECl结果分别为0.539%(0.430%,1.283%)和0.829%(0.119%,1.298%),均提示对氢氯噻嗪无反应,组间差异无统计学意义(U=130.000,P=0.956)。结论GS患者中低尿钙比例为63.86%,尿钙水平与疾病临床表型、NCC功能损伤严重程度之间均无明确相关性。     

Fibrinogen-thrombin collagen patch reinforcement of highrisk colonic anastomoses in rats

AIM To evaluate the effectiveness of human fibrinogenthrombin collagen patch(TachoSil~?) in the reinforcement of high-risk colon anastomoses.METHODS A quasi-experimental study was conducted in Wistar rats(n = 56) that all underwent high-risk anastomoses(anastomosis with only two sutures) after colectomies. The rats were divided into two randomized groups: Control group(24 rats) and treatment group(24 rats). In the treatment group, high-risk anastomosis was reinforced with TachoSil~? (a piece of Tacho Sil? was applied over this high-risk anastomosis, covering the gap). Leak incidence, overall survival, intra-abdominal adhesions, and histologic healing of anastomoses were analyzed. Survivors were divided into two subgroups and euthanized at 15 and 30 d after intervention in order to analyze the adhesions and histologic changes. RESULTS Overall survival was 71.4% and 57.14% in the TachoSil~? group and control group, respectively(P = 0.29); four rats died from other causes and six rats in the treatment group and 10 in the control group experienced colonic leakage(P 0.05). The intra-abdominal adhesion score was similar in both groups, with no differences between subgroups. We found non-significant differences in the healing process according to the histologic score used in both groups(P = 0.066).CONCLUSION In our study, the use of TachoSil~? was associated with a non-statistically significant reduction in the rate of leakage in high-risk anastomoses. TachoSil~? has been shown to be a safe product because it does not affect the histologic healing process or increase intra-abdominal adhesions.